Baltic Biotech Landscape 2026: Lithuania, Latvia, Estonia

Lithuania concentrates 40 operators in the directory, making it the largest Baltic biotech and pharma geography. Vilnius is the operating centre — Northway Biotech and Biotechpharma (both under the Northway group) run biologics CDMO manufacturing at BIO CITY Vilnius; Thermo Fisher Scientific Baltics and Thermo Fisher Supply Vilnius hold the regional reagent and supply footprint; Vilnius University Life Sciences Center anchors academic biotechnology research; CasZyme, Biomatter, Droplet Genomics, and Atrandi Biosciences operate the Vilnius genomics and molecular-tools layer; Sanobiotec runs pharmaceutical manufacturing; World Courier Baltics runs the region’s GDP-certified vault and logistics operation from Vilnius. Kaunas adds Biomapas as the Baltic full-service CRO anchor, Innovation Center Kaunas as the cluster hub, Aconitum as a traditional pharma manufacturer, and several smaller biotech operators. Klaipeda, Šiauliai, and Telšiai add regional manufacturing and research entries. The Lithuanian drug regulator VVKT sits in Vilnius. See the BIO CITY Vilnius brief for the detailed case study on Lithuania’s anchor biotech site.

Latvia concentrates 17 operators, most of them in or near Riga. The country’s biotech and pharma profile leans towards chemical and small-molecule CDMO manufacturing rather than biologics. AS Grindeks is one of Latvia’s largest diversified pharmaceutical manufacturers by reported revenue. Olpha (listed in the directory as Olainfarm, rebranded Olpha in 2023) and PharmIdea operate out of Olaine and run chemical CDMO services. Lotos Pharma, Silvanols, Silvanols Pharma, and Kalceks provide pharma manufacturing and healthcare product capacity. The Latvian Institute of Organic Synthesis anchors academic and applied chemistry research. BIOR operates as the national food-and-veterinary research institute with pharma-adjacent scope. The Latvia Pharma Cluster hub operates as the Riga-based industry association. ZVA is the national drug regulator. On the clinical-services side, Inpharmatis and E. Gulbis Laboratory serve as Latvian CRO and diagnostics layer. GenEra adds a diagnostics entry, Biosan provides laboratory tools, PrintyMed and Cellbox Labs cover biotech-adjacent manufacturing.

Estonia concentrates 17 operators split between Tartu (the university and research city) and Tallinn (the commercial and diagnostics city). Tartu is the genomics and research cluster: the Estonian Genome Center anchors the national population biobank, Icosagen Group provides biologics CDMO and antibody development, Solis BioDyne manufactures molecular-biology reagents, TBD Pharmatech provides drug-development services, BioCC runs infection-biology research services, Asper Biogene operates clinical genetic diagnostics, PharmaSynth provides pharmaceutical manufacturing, Antegenes adds diagnostics, and Power Algae plus Arpengen cover smaller biotech specialties. Tartu also hosts the Estonian drug regulator Ravimiamet and the University of Tartu research infrastructure. Tallinn adds Synlab Estonia (laboratory diagnostics), HansaBioMed Life Sciences (extracellular vesicle biotech), TFTAK (food and bio-processing research), and Gelatex Technologies (biomaterials).

Four capabilities stand out. First, biologics CDMO at clinical and mid-scale commercial — Northway Biotech (Vilnius) is the Baltic biologics CDMO anchor, with Biotechpharma and Icosagen Group adding depth. Second, chemical CDMO and small-molecule manufacturing — Grindeks, Olpha, PharmIdea, PharmaSynth, and Lotos Pharma form an EU-internal chemical-CDMO layer competitive on cost and regulatory alignment. Third, genomics and molecular diagnostics — CasZyme (CRISPR IP), Droplet Genomics, Atrandi Biosciences, Asper Biogene, Saidė Genomics, and the Estonian Genome Center give the region a density of genomics-layer operators the rest of CEE does not match. Fourth, clinical research — Biomapas, Cureline Baltic, and Inpharmatis provide full-service CRO, biospecimen, and clinical-services capacity. The Baltic CRO Landscape brief goes deeper on the clinical-research layer.

The Baltics sit inside the EU single market, with no customs friction on intra-EU biotech shipments. GDP-certified logistics run through Vilnius (World Courier Baltics vault, Thermo Fisher Supply Vilnius), with Riga and Tallinn as regional extensions; downstream movement into and out of Germany and Poland uses the DHL Life Sciences & Healthcare and Kuehne+Nagel Healthcare hubs sited in those countries. The Baltic-German supply chain brief maps how Baltic operators connect into Polish discovery capacity and German commercial manufacturing. For sponsors, the practical implication is that a Baltic CDMO, CRO, or diagnostics engagement runs on the same GDP + CTIS rails as Germany or Poland — no separate operating framework is needed.

Three sponsor archetypes see the most value. First, mid-cap biotech sponsors running clinical-to-mid-scale biologics programmes — Northway Biotech at BIO CITY Vilnius is the natural European biologics CDMO option at that scale with lower operating cost than German equivalents. Second, sponsors running EU-regulated clinical trials that need English-fluent, EU-aligned CRO capacity — Biomapas covers full-service CRO, Cureline Baltic covers biospecimen, Inpharmatis covers Latvian clinical services. Third, genomics, molecular-diagnostics, and translational-research programmes — the Baltic genomics cluster (CasZyme, Droplet Genomics, Atrandi, Asper Biogene, Estonian Genome Center) offers a density of operators that EU-internal sponsors can reach without leaving the single market. Memel Biotech directory entries link to each operator’s official site for direct verification.